ArticleRSC chemical biology2026
Keap1-Kelch-targeting protein-protein interaction inhibitors, but not reversibly-binding electrophiles, increase the thermostability of Keap1 in the cellular environment.
Article in RSC chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-p45-related factor 2 (Keap1/Nrf2) partnership orchestrates the cellular defence against oxidative, inflammatory and metabolic stress. Dysregulation of Nrf2 is involved in the pathogenesis of numerous chronic diseases. Under homeostatic conditions, Keap1 continuously targets Nrf2 for ubiquitination and degradation. When Keap1 is inactivated, Nrf2 accumulates and translocates to the nucleus, where it activates transcription of genes encoding cytoprotective proteins. There are two main types of Keap1 inhibitors, electrophiles and Keap1-Nrf2 protein-protein interaction (PPI) inhibitors. Using a quantitative fluorescence-based cellular thermal shift assay (CETSA), we investigated the ability of a panel of electrophilic Nrf2 activators and PPI inhibitors to bind to Keap1 in lysates and intact cells stably expressing Keap1-mCherry or free mCherry as controls. All PPI inhibitors tested caused an increase in the thermostability of Keap1-mCherry. Surprisingly however, electrophiles that bind covalently and reversibly to thiols did not. Moreover, treatment of intact cells with the double Michael acceptors bis(benzylidene)acetone and its hydroxylated derivative bis(2-hydroxybenzylidene)acetone caused a decrease in the thermostability of Keap1. Thus, in addition to confirming target engagement of Keap1-targeting PPI inhibitors in the cellular environment, the Keap1 fluorescence-based CETSA is capable of distinguishing between the mechanism of action of the two types of Nrf2 activators in the cellular environment, and has the potential for cost-effective, high-throughput applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.